

Indian startup ZeroHarm Sciences plans expansion to UK & GCC markets

13 June 2025 | News

India's first nanotech-driven nutraceutical brand accelerates global scale-up



ZeroHarm Sciences, India's pioneering clean-label nutraceutical company, is embarking on an aggressive global expansion, targeting the United Kingdom and GCC markets, including the UAE and wider Middle East.

Riding a 10x revenue growth over the past two years and operating at a strong ~20% EBITDA margin, the startup aims to double its revenue by FY 2026. This move builds on its growing success in the United States, which now contributes nearly 30% of its total revenue.

At the heart of ZeroHarm's global success is its patented ZeroHarm BioEnhance platform, a pharma-grade nanotechnology that encapsulates plant-based actives at the nanoscale, dramatically enhancing their bioavailability by up to 5x, ensuring faster onset, precise dosing, and residue-free delivery. This breakthrough, backed by granted patents and deep R&D, makes ZeroHarm the first Indian company to bring pharmaceutical nanotech into nutraceuticals at scale.

ZeroHarm's US FDA, CE, and ISO-certified formulations are backed by government-led clinical trials, with documented claims for 15 products, setting it apart in a market rife with unverified health claims.

Backed by a fully owned, nanotech-enabled manufacturing facility, ZeroHarm can produce up to Rs 250 crore worth of finished goods annually, making it one of the few Indian nutraceutical brands with true end-to-end production capabilities.

To support its international expansion, ZeroHarm has acquired a dedicated manufacturing and R&D facility in the United States, enhancing local supply chain efficiency, fast-tracking formulation innovation, and enabling closer clinical and regulatory collaborations in key global markets. The US infrastructure also gives ZeroHarm a significant strategic edge in developed markets, where stringent compliance standards often limit entry for Indian nutraceutical brands reliant on contract manufacturing.

With distribution agreements and regulatory filings already underway, the company will launch in the UK and GCC markets by Q4 2025, introducing its clinically tested product lines via pharmacies, e-commerce platforms, and integrative practitioner networks.